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In cancer, the FOXO family of transcription factors functions as tumor suppressors and is directly
inactivated by oncogenic signaling through the PI3K/AKT pathway. Now, Skykes et al. (2011) iden-
tify a paradoxical requirement for FOXOs in the maintenance of leukemia-initiating cells.The PI3K/AKT/mTOR pathway regulates
proliferation, growth, survival, and a
cell’s response to hypoxia and energy
depletion. Activation of this pathway is
observed in the majority of cancers,
including 50% of human acute myeloid
leukemias (AML) (Martelli et al., 2010).
The serine/threonine protein kinases
AKT and mTOR play central roles in this
pathway by controlling the activity of
a large number of downstream targets,
including the Forkhead Box-containing
transcriptional factors FOXO1, FOXO3,
and FOXO4 (referred to collectively as
FOXOs) (Figure 1). The FOXO family
controls a transcriptional network that
induces quiescence, protection from
oxidative stress, and, in some cells,
apoptosis (Fu and Tindall, 2008).
The PI3K/AKT/mTOR pathway nega-
tively regulates the activity of the FOXOs
through AKT-mediated phosphorylation,
which results in nuclear exclusion and
inhibition of transcriptional activity (Fig-
ure 1). Moreover, the FOXOs were initially
identified as the targets of chromosomal
translocations in human alveolar rhabdo-
myosarcoma (i.e., a type of muscle
cancer) (FOXO1) and acute leukemia
(FOXO3 and FOXO4). In these transloca-
tions, the encoded fusion proteins lack
the FOXO DNA-binding domain, consis-
tent with a loss of function. In addition,
deletions of all three FoxO genes in
the mouse result in the development of
lymphoblastic thymic lymphomas and
fatal hemagiomas that can progress to
angiosarcomas (Paik et al., 2007). Collec-
tively, these data suggest that PI3K/AKT/
mTOR signaling contributes to tumor
formation, in part, by inhibiting the activity
of the FOXOs’ tumor suppressors. In thisissue of Cell, Sykes et al. (2011) demon-
strate a surprising positive role for FOXOs
in the maintenance of the immature state
of leukemia-initiating cells in AMLs, a
rare population of leukemic cells that,
like normal stem cells, have the ability to
self-renew and differentiate. How could
FOXOs play such apposed roles in tumor-
igenesis?
Using amousemodel thatmimics AMLs
containing a translocation between chro-
mosomes 9 and 11 (i.e., t(9;11)) which
results in a fusion between the mixed-
lineage leukemia gene (MLL) and the AF9
gene, Sykes et al. demonstrate that the
leukemia-initiating cells have attenuated
AKT activation in response to growth
factor stimulation. Moreover, forced acti-
vation of AKT in the leukemia-initiating
cells leads to decreased growth, cellular
differentiation, and apoptosis. As pre-
dicted, the decreased AKT activity in
leukemia-initiating cells is associated with
an increase in nuclear FOXOs and a tran-
scriptional profile that is consistent with
FOXO activation. Remarkably, conditional
deletion of Foxo1, Foxo3, and Foxo4 in the
MLL-AF9model decreasescolony forming
ability, promotes myeloid differentiation,
and decreases levels of LIC. These effects
translate into a decrease in leukemic
burden in vivo. Importantly, Sykes et al.
thenextend theseobservations toasubset
of humanAMLcell lines andprimary leuke-
mias, including some that lack aMLL rear-
rangement. These data suggest that
increased FOXO activity is required to
maintain the immature state of leukemia-
initiating cells by directly preventing their
differentiation and apoptosis (Figure 1).
Another interesting finding comes
when Sykes and colleagues analyze theCell 146, Sleukemia cells that persist after deletion
of FOXOs (i.e., cells resistant to the anti-
leukemic activity of depleting FOXOs).
In these cells, reduced FOXO activity
induces activation of the JNK/cJUN
pathway (Figure 1). Treating these cells
with an inhibitor of JNK kinase leads to
a decrease in cell growth, suggesting
that JNK activity may partially mitigate
the antileukemic activity of depleting
FOXOs. This is consistent with data sug-
gesting that JNK activation increases
nuclear levels of FOXOs (Greer and
Brunet, 2005), although other pathways
downstream of activated JNK may also
come into play. An interesting practical
implication of these data is that inhibition
of the JNK pathway may have a thera-
peutic benefit in a subset of AMLs.
Although these data run counter to the
established function of FOXOs as tumor
suppressor, FOXOs’ role in maintaining
normal hematopoietic stem cells (HSC)
provides some insights into what may
be occurring in leukemia-initiating cells.
Loss of FoxO1/3/4 in mice, despite in-
ducing lymphoblastic thymic lymphomas,
leads to a decrease in the levels of long-
term HSCs, partially because of a loss of
their quiescent state and an increase in
apoptosis (Tothova et al., 2007). FoxO3
activity appears critical for maintaining
the self-renewal activity of HSCs (Miya-
moto et al., 2007). Similarly, loss of Pten
or constitutive activation of AKT, although
inducing leukemia, also leads to a deple-
tion of normal HSCs (Yilmaz et al., 2006;
Kharas et al., 2010; Lee et al., 2010). In
contrast to their effects on normal HSCs,
both Pten loss and AKT activation induce
an expansion of leukemia-initiating cells,
the opposite of what is seen with theeptember 2, 2011 ª2011 Elsevier Inc. 669
Figure 1. FOXOs as Both Tumor Suppressors and Cancer Genes
The transcription factors FOXO1, FOXO3, and FOXO4 (i.e., ‘‘the FOXOs’’) induce cell-cycle arrest and
apoptosis and contribute to the detoxification of reactive oxygen species (ROS). Through these pathways,
FOXOs play a tumor suppressor role in a variety of cancers. Oncogenic signaling through the PI3K/AKT/
mTOR pathway inhibits the tumor suppressor activity of the FOXOs by AKT-mediated phosphorylation,
resulting in their exclusion from the nucleus and degradation. In contrast to cancer cells, normal hema-
topoietic stem cells (HSCs) require FOXOs for their maintenance. Counter to their tumor suppressor role,
the FOXOs are also required to maintain leukemia-initiating cells (LIC) in a subset of acute myeloid
leukemias (Sykes et al., 2011). Moreover, loss of FOXOs in LIC induces an increase in the activity of the
JNK kinase, which counters the consequences of disrupting FOXO. This, in part, results from a positive
effect of JNK on FOXO nuclear localization, although the exact mechanisms through which JNK induces
FOXO nuclear localization remain incompletely defined.deletion of FoxOs. However, it is impor-
tant to remember that, despite a depen-
dence of some AMLs on FOXO activity,
lymphoblastic thymic lymphoma develop
in the absence of FoxOs in mice, and in
human AML, almost 50% of cases have
evidence of activated AKT, resulting in
a decrease in FOXO activity. Thus, not
all leukemia-initiating cells depend on
FOXO activity to expand.
So how do we reconcile the disparate
activities observed in normal and leuke-
mic cells, as well as the contrasting activ-
ities of different members of the PI3K/
AKT/mTOR/FOXO pathway? First, it is
important to remember that PI3K/AKT/
mTOR is not a simple linear pathway
that culminates in the inhibition of FOXOs.
Activation of the pathway at different
points launches profoundly different670 Cell 146, September 2, 2011 ª2011 Elsedownstream signals. Second, signaling
through these pathways depends on the
context and can vary not only between
lineages, but also within a given lineage,
depending on a cell’s stage of devel-
opment and differentiation. Consistent
with these observations, loss of Pten
leads to a high frequency of AML, where-
as constitutive activation of AKT or loss
of FoxO1/3/4 primarily leads to T cell
lymphomas instead of AML.
Evenwith these caveats,we are left with
more questions than answers. For
instance, what pathways control a cell’s
response to the activation of PI3K/AKT
or loss of FOXOs, and what dictates a
common effect in normal HSCs but mark-
edly different effects in leukemia-initiating
cells? Also, do cooperating oncogenic
mutations allow some leukemias to by-vier Inc.pass the requirement for FOXO activity,
and will inhibition of JNK activity in leuke-
mias with reduced FOXO activity offer
tangible therapeutic benefits in patients?
Clearly, additional studies on the PI3K/
AKT/mTOR/FOXO pathway in normal
and leukemic HSCs are necessary. It will
also be important to accurately define
the mutational status and functional
activity of the individual components of
this pathway in leukemias and to correlate
thesewith a patient’s response to therapy.
Only once these types of data are in hand
can we then develop a rational approach
to target this pathway in leukemia and
other cancers.
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